| 摘要 |
A triazine derivative or a N-oxide, a pharmaceutically acceptable addition salt or a stereochemically isomeric form thereof has the formula I' wherein: p is 0, 1, 2, 3 or 4; q is 0, 1, 2, 3, 4 or 5; R1 is hydrogen, alkyl, mono or di(alkyl) aminoalkyloxy, mercapto, alkylthio, cycloalkyl, aryl or alkyl substituted with mono or di(alkyl)amino, alkyloxy, aryl or Het; R2 is -C(=X)-Y-R5; X is O or S; Y is a direct bond; R5 is Het; each R3 and R4 are independently halo, haloalkyl, alkyl, hydroxy, alkyloxy, alkylcarbonyloxy, mercapto, alkylthio, alkylsulphonyl, alkylsulphinyl, haloalkylsulphonyl, aryl, cyano, nitro, amino, mono or di(alkyl)amino or (alkylcarbonyl)amino; aryl is optionally substituted phenyl and Het is optionally substituted pyrrolyl, pyrrolinyl, imidazolyl, imidazolinyl, pyrazolyl, pyrazolinyl, triazolyl, tetrazolyl, furanyl, tetrahydrofuranyl, thienyl, thiolanyl, dioxolanyl, oxazolyl, oxazolinyl, isoxazolyl, thiazolyl, thiazolinyl, isothiazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyranyl, pyridazinyl, morpholinyl, thiomorpholinyl, dioxanyl, dithianyl, trithianyl, triazinyl, benzothienyl, isobenzothienyl, benzofuranyl, isobenzofuranyl, benzthiazolyl, benzoxazolyl, indolyl, isoindolyl, indolinyl, purinyl, benzimidazolyl, quinolyl, isoquinolyl, cinnolinyl, phtalazinyl, quinazolinyl, quinoxalinyl or thiazolopyridinyl. A pharmaceutical composition thereof is useful for treating eosinophil-dependent inflammatory diseases. The compound defined above can also be used to mark or identify a receptor by radiolabeling the compound, administering the compound to biological material and detecting emissions from the compound. |
